At a glance
ClinicalIndex Comparison RecordN/ACompleted· 805 enrolled
Drug / intervention
No drugother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)
In Brief
An observational study evaluating No drug for Gastric Cancer and Gastroesophageal Junction Cancer. Completed, enrolled 805 participants across 9 sites.
Detailed Summary
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Gastroesophageal Junction Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20252026
Enrollment StartAug 2024
First PostedSep 2024
Primary CompletionJul 2025
TodayJul 2026
First PostedSep 5, 2024
Enrollment StartAug 15, 2024
Primary CompletionJul 30, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 1.8 years ago
Interventions
No drugother
This is a non-interventional study and no study drug will be provided.